Tetracycline News and Research

RSS

Tetracycline is an antibiotic drug used to treat infection.

Detrimental effect of tetracycline on male reproductive function, sperm viability of pseudoscorpions

In a paper published today in Nature's open access journal Scientific Reports, researchers at the University of Nevada, Reno report that male pseudoscorpions treated with the antibiotic tetracycline suffer significantly reduced sperm viability and pass this toxic effect on to their untreated sons. They suggest that a similar effect could occur in humans and other species.

30 Apr 2012

Novel tetracyclines with improved potency, efficacy against contemporary P. aeruginosa isolates

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results from studies that demonstrate the improved potency and pharmacokinetics of several of its newest discovery-stage tetracycline analogs.

2 Apr 2012

Combined therapy effective in treating patients with severe facial acne

A combined therapy of common acne medications was shown to be a potent regimen for treating patients with severe facial acne, according to two published studies involving Henry Ford Hospital.

15 Mar 2012

Study: MRSA jumps from food animals to humans

A strain of the potentially deadly antibiotic-resistant bacterium known as MRSA has jumped from food animals to humans, according to a new study involving two Northern Arizona University researchers.

22 Feb 2012

Researchers discover identical antibiotic resistant genes in soil bacteria and in pathogens from clinics

Disease-causing bacteria's efforts to resist antibiotics may get help from their distant bacterial relatives that live in the soil, new research at Washington University School of Medicine suggests.

21 Feb 2012

Mylan's generic Doryx ANDA receives final FDA approval

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg. This product is the generic version of Mayne Pharma's Doryx, which is a tetracycline-class antimicrobial.

9 Feb 2012

Gal-pagos reptiles living near human settlements harbor antibiotic-resistant bacteria

Land and marine iguanas and giant tortoises living close to human settlements or tourist sites in the Gal-pagos islands are more likely to harbor antibiotic-resistant bacteria than those living in more remote or protected sites on the islands, researchers report in a new study.

24 Jan 2012

New silk-based microneedle system for controlled-release drug delivery

Bioengineers at Tufts University School of Engineering have developed a new silk-based microneedle system able to deliver precise amounts of drugs over time and without need for refrigeration. The tiny needles can be fabricated under normal temperature and pressure and from water, so they can be loaded with sensitive biochemical compounds and maintain their activity prior to use. They are also biodegradable and biocompatible.

22 Dec 2011

Study identifies tertiary treatment as an important source of antibiotic resistant genes

Water discharged into lakes and rivers from municipal sewage treatment plants may contain significant concentrations of the genes that make bacteria antibiotic-resistant. That's the conclusion of a new study on a sewage treatment plant on Lake Superior in the Duluth, Minn., harbor that appears in ACS' journal Environmental Science & Technology.

8 Dec 2011

Sore throat among young adults taking antibiotics for acne: Study

A new study reveals that young adults who take oral antibiotics for acne may be more likely to get sore throats. The reason behind this is unclear say researchers. However they add that long-term use of antibiotics might change the balance of bacteria in the throat. In principle, that could allow infection-causing strains to multiply.

22 Nov 2011

Xylitol can prevent inner ear infections in healthy children

There is "fair evidence" to support the use of xylitol, a natural sweetener used in gums and mints, to prevent inner ear infections in healthy children, a new evidence review finds.

11 Nov 2011

Four companies receive NIAID contracts to develop broad-spectrum therapeutics

Four companies are to develop broad-spectrum therapeutics-antibiotics, antivirals and an antitoxin-to prevent or treat diseases caused by multiple types of bacteria or viruses, under contracts awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

14 Oct 2011

Antibiotic-resistant Salmonella worries experts

According to an international team of researchers a strain of Salmonella that is resistant to important antibiotics has spread from Africa to Europe in recent years and has been spotted in a few samples of imported spices in the United States.

4 Aug 2011

Low-level antibiotic exposure may cause E. coli bacteria to develop resistance

E. coli bacteria exposed to three common antibiotics were more likely to develop antibiotic resistance following low-level antibiotic exposure than after exposure to high concentrations that would kill the bacteria or inhibit their growth, according to a timely article in Microbial Drug Resistance, a peer-reviewed journal published by Mary Ann Liebert, Inc.

15 Jun 2011

Analysis of Nubian-era mummies finds schistosomiasis spread from altering environment

Mummies from along the Nile are revealing how age-old irrigation techniques may have boosted the plague of schistosomiasis, a water-borne parasitic disease that infects an estimated 200 million people today.

24 May 2011

Tetraphase presents TP-434, TP-2758 antibiotics study data against pathogens at ECCMID

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results of several studies designed to support the continued advancement of its lead antibiotic, TP-434, a potent new broad-spectrum intravenous antibiotic with oral stepdown potential effective against difficult-to-treat and multidrug-resistant pathogens.

10 May 2011

Researchers temporarily turn off essential gene using RNAi technology

One way of discovering a gene's function is to switch it off and observe how the loss of its activity affects an organism. If a gene is essential for survival, however, then switching it off permanently will kill the organism before the gene's function can be determined. Researchers at Cold Spring Harbor Laboratory (CSHL) have overcome this problem by using RNA interference (RNAi) technology to temporarily turn off any essential gene in adult mice and then turn it back on before the change kills the animals.

15 Apr 2011

Therapeutic potential of iPS cells may be limited by reprogramming errors and genomic instability

In the past few months, a slew of papers have indicated that the therapeutic potential of a promising type of stem cell, called induced pluripotent stem (iPS) cells, might be limited by reprogramming errors and genomic instability. iPS cells are engineered by reprogramming fully differentiated adult cells, often skin cells, back to a primitive, embryonic-like state.

9 Mar 2011

Impax' NDA for generic version of Adoxa receives final FDA approval

Impax Laboratories, Inc. today announced that the U.S. Food and Drug Administration has granted final approval of the Company's Abbreviated New Drug Application for its generic version of Adoxa.

18 Feb 2011

FDA approves Impax's ANDA for generic Doryx 75 and 100mg tablets

Impax Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company's Abbreviated New Drug Application for the generic version of Doryx® (doxycyline hyclate delayed-release) 75 and 100mg tablets. The Company is preparing for product launch through Global Pharmaceuticals, Impax's generic division.

29 Dec 2010